These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 33672884)

  • 1. Clinical Candidates Targeting the ATR-CHK1-WEE1 Axis in Cancer.
    Gorecki L; Andrs M; Korabecny J
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33672884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells.
    Vera J; Raatz Y; Wolkenhauer O; Kottek T; Bhattacharya A; Simon JC; Kunz M
    Cell Signal; 2015 May; 27(5):951-60. PubMed ID: 25683911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanding roles of cell cycle checkpoint inhibitors in radiation oncology.
    Hauge S; Eek Mariampillai A; Rødland GE; Bay LTE; Landsverk HB; Syljuåsen RG
    Int J Radiat Biol; 2023; 99(6):941-950. PubMed ID: 33877959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological targeting the ATR-CHK1-WEE1 axis involves balancing cell growth stimulation and apoptosis.
    Mak JP; Man WY; Ma HT; Poon RY
    Oncotarget; 2014 Nov; 5(21):10546-57. PubMed ID: 25301733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mangiferin induces cell cycle arrest at G2/M phase through ATR-Chk1 pathway in HL-60 leukemia cells.
    Peng ZG; Yao YB; Yang J; Tang YL; Huang X
    Genet Mol Res; 2015 May; 14(2):4989-5002. PubMed ID: 25966274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis.
    Bukhari AB; Lewis CW; Pearce JJ; Luong D; Chan GK; Gamper AM
    J Clin Invest; 2019 Mar; 129(3):1329-1344. PubMed ID: 30645202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting lung cancer through inhibition of checkpoint kinases.
    Syljuåsen RG; Hasvold G; Hauge S; Helland Å
    Front Genet; 2015; 6():70. PubMed ID: 25774168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells.
    Mak JP; Man WY; Chow JP; Ma HT; Poon RY
    Oncotarget; 2015 Aug; 6(25):21074-84. PubMed ID: 26025928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA damage checkpoint kinases in cancer.
    Smith HL; Southgate H; Tweddle DA; Curtin NJ
    Expert Rev Mol Med; 2020 Jun; 22():e2. PubMed ID: 32508294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Potential for Targeting G
    Melia E; Parsons JL
    Cancers (Basel); 2024 Aug; 16(17):. PubMed ID: 39272874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. G2-checkpoint targeting and radiosensitization of HPV/p16-positive HNSCC cells through the inhibition of Chk1 and Wee1.
    Busch CJ; Kröger MS; Jensen J; Kriegs M; Gatzemeier F; Petersen C; Münscher A; Rothkamm K; Rieckmann T
    Radiother Oncol; 2017 Feb; 122(2):260-266. PubMed ID: 27939202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting replication stress response using polypurine reverse hoogsteen hairpins directed against WEE1 and CHK1 genes in human cancer cells.
    Aubets E; Noé V; Ciudad CJ
    Biochem Pharmacol; 2020 May; 175():113911. PubMed ID: 32173365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress.
    Saini P; Li Y; Dobbelstein M
    Oncotarget; 2015 May; 6(15):13072-87. PubMed ID: 25965828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential properties of mitosis-associated events following CHK1 and WEE1 inhibitor treatments in human tongue carcinoma cells.
    Nojima H; Homma H; Onozato Y; Kaida A; Harada H; Miura M
    Exp Cell Res; 2020 Jan; 386(2):111720. PubMed ID: 31738907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the S and G2 checkpoint to treat cancer.
    Chen T; Stephens PA; Middleton FK; Curtin NJ
    Drug Discov Today; 2012 Mar; 17(5-6):194-202. PubMed ID: 22192883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATR/CHK1 inhibitors and cancer therapy.
    Qiu Z; Oleinick NL; Zhang J
    Radiother Oncol; 2018 Mar; 126(3):450-464. PubMed ID: 29054375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress.
    Young LA; O'Connor LO; de Renty C; Veldman-Jones MH; Dorval T; Wilson Z; Jones DR; Lawson D; Odedra R; Maya-Mendoza A; Reimer C; Bartek J; Lau A; O'Connor MJ
    Cancer Res; 2019 Jul; 79(14):3762-3775. PubMed ID: 31123088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CHK1 Inhibitor Blocks Phosphorylation of FAM122A and Promotes Replication Stress.
    Li F; Kozono D; Deraska P; Branigan T; Dunn C; Zheng XF; Parmar K; Nguyen H; DeCaprio J; Shapiro GI; Chowdhury D; D'Andrea AD
    Mol Cell; 2020 Nov; 80(3):410-422.e6. PubMed ID: 33108758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
    Haynes B; Murai J; Lee JM
    Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance.
    Zheng H; Shao F; Martin S; Xu X; Deng CX
    Sci Rep; 2017 Mar; 7():43517. PubMed ID: 28262781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.